| 3.15 0.28 (9.76%) | 10-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.94 |
1-year : | 4.61 |
| Resists | First : | 3.38 |
Second : | 3.94 |
| Pivot price | 2.62 |
|||
| Supports | First : | 2.65 |
Second : | 2.2 |
| MAs | MA(5) : | 2.88 |
MA(20) : | 2.59 |
| MA(100) : | 2.84 |
MA(250) : | 3.92  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 88.5 |
D(3) : | 87 |
| RSI | RSI(14): 72.9 |
|||
| 52-week | High : | 6.5 | Low : | 2.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ OBIO ] has closed It is unclear right now based on current values. 40.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.38 - 3.4 | 3.4 - 3.41 |
| Low: | 2.82 - 2.84 | 2.84 - 2.85 |
| Close: | 3.12 - 3.15 | 3.15 - 3.17 |
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Thu, 09 Oct 2025
Orchestra BioMed Presents Comprehensive Data on AVIM Therapy for Hypertensive Heart Disease at Georgia Innovation Summit - Quiver Quantitative
Thu, 09 Oct 2025
15.6 mmHg Immediate aSBP Drop — Orchestra BioMed AVIM Data; FDA Breakthrough, Oct 10 - Stock Titan
Tue, 07 Oct 2025
Orchestra BioMed Reports Q1 2025 Financial Results and Advances Key Clinical Programs - MSN
Tue, 12 Aug 2025
Orchestra BioMed Lands $111M Strategic Investment and FDA Breakthrough Status for Heart Disease Tech - Stock Titan
Tue, 12 Aug 2025
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 3.207e+007 (%) |
| Held by Institutions | 16 (%) |
| Shares Short | 564 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.094e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 311.8 % |
| Return on Equity (ttm) | -77.4 % |
| Qtrly Rev. Growth | 2.94e+006 % |
| Gross Profit (p.s.) | 12.71 |
| Sales Per Share | -531.9 |
| EBITDA (p.s.) | 4.62712e+006 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -59 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 185.85 |
| Dividend | 0 |
| Forward Dividend | 736660 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|